FINWIRES · TerminalLIVE
FINWIRES

$NGNE

2 stories mentioning NGNEUpdated 136d ago

Every FINWIRES story that references NGNE, newest first.

What are analysts saying about NGNE?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on NGNE?

Insider Trading

Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing

Christine Mikail Cvijic, Director, President and CFO, on May 06, 2026, sold 9,600 shares in Neurogene (NGNE) for $300,043. Following the Form 4 filing with the SEC, Cvijic has control over a total of 93,640 common shares of the company, with 93,640 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1404644/000154366326000013/xslF345X05/wk-form4_1778255465.xmlPrice: $30.50, Change: $-0.76, Percent Change: -2.43%

$NGNE
Research

Guggenheim Initiates Neurogene at Buy With $69 Price Target

Neurogene (NGNE) has an average rating of buy and mean price target of $76.43, according to analysts polled by FactSet.

$NGNE

Track with the FINWIRES app suite

FolioX
FolioX
Track NGNE in your portfolio
WheelAI
WheelAI
Analyze NGNE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on NGNE